Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible
Commercial Sponsor
Bristol-Myers Squibb (BMS)
Summary
Eligible patients will be randomised to receive:
(1) Neoadjuvant nivolumab + NKTR-214, followed by radical cystectomy (RC), followed by adjuvant nivolumab + NKTR-214.
(2) Neoadjuvant nivolumab, followed by RC, followed by adjuvant nivolumab. Or,
(3) RC alone, without neoadjuvant or adjuvant therapy